2017 Runner-Up

Mekonos is developing a new approach for non-viral cell engineering using a proprietary silicon nano-robotic chip (KAREL) that delivers biomaterial or molecules into potentially, millions of individual cells. This will see a dramatic breakthrough in the genetic engineering treatment of diseases such as cancer. Instead of the more traditional method of using viruses which can cause cancers and are very expensive, our safe, precise and fast silicon based technology, when fully developed will result in an estimated 20-30x cost reduction and a 1000x throughput improvement over competitors.